Strongbridge Biopharma PLC (SBBP)
| Market Cap | 174.17M |
| Revenue (ttm) | 32.44M |
| Net Income (ttm) | -44.19M |
| Shares Out | 67.38M |
| EPS (ttm) | -0.72 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 29 |
| Last Price | $2.48 |
| Previous Close | $2.57 |
| Change ($) | -0.09 |
| Change (%) | -3.50% |
| Day's Open | 2.58 |
| Day's Range | 2.46 - 2.59 |
| Day's Volume | 385,778 |
| 52-Week Range | 1.87 - 4.40 |
DUBLIN, Ireland and TREVOSE, Pa., July 29, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP) (“Strongbridge”), a global commercial-stage biopharmaceutical company focused on the develo...
DUBLIN, Ireland and TREVOSE, Pa., July 29, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commerc...
Strongbridge Biopharma (SBBP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DUBLIN, Ireland and TREVOSE, Pa., July 26, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commerci...
~ Study Confirms Long-Term Treatment with KEVEYIS is Safe and Effective for Chronic Use ~
NEW YORK, June 15, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: First Bancorp (NASDAQ: FBNC) concerning potential vio...
DUBLIN, Ireland and TREVOSE, Pa., June 03, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commerc...
NEW YORK, May 29, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action ...
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Strongbridge Bioph...
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Strongbridge Biopharma plc (NASDAQ: SBBP) to Xeris Pharmaceuticals, Inc. is fair to S...
NEW YORK, May 24, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Strongbridge Biopharma plc ("Strongbridg...
CHICAGO and DUBLIN and TREVOSE, Pa., May 24, 2021 /PRNewswire/ -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a pharmaceutical company leveraging its novel formulation technology platforms to develop an...
Penny stocks are in focus as we enter the last week of May. Which companies are you watching?
Xeris Pharmaceuticals Inc (NASDAQ: XERS) has agreed to acquire Strongbridge Biopharma plc (NASDAQ: SBBP) for stock and contingent value rights (CVRs), valuing Strongbridge at approximately $267 million....
CHICAGO & DUBLIN & TREVOSE, Pa.--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (“Xeris”) (Nasdaq: XERS), a pharmaceutical company leveraging its novel formulation technology platforms to develop and comm...
CHICAGO & DUBLIN & TREVOSE, Pa.--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ...
The FDA has accepted to review Strongbridge Biopharma plc's (NASDAQ: SBBP) marketing application for Recorlev (levoketoconazole) to treat endogenous Cushing's syndrome. Earlier than anticipated, the Com...
Strongbridge Biopharma (SBBP) delivered earnings and revenue surprises of -10.00% and 2.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Shares of Strongbridge Biopharma (NASDAQ:SBBP) fell 3.7% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 42.11% over the past year to ($0.11), whic...
~ Reports KEVEYIS ® (dichlorphenamide) First Quarter 2021 Revenue of $8.4 Million, a 25 Percent Increase Compared to $6.7 Million of Revenue During First Quarter of 2020 ~
On Wednesday, May 12, Strongbridge Biopharma (NASDAQ:SBBP) will release its latest earnings report. Benzinga's report can help you figure out the ins and outs of the earnings release.
DUBLIN, Ireland and TREVOSE, Pa., May 06, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commerci...
Strongbridge Biopharma (SBBP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
RECORLEV® (levoketoconazole) Treatment Demonstrates Clinically Meaningful Improvements in Cortisol Control and Clinical Benefit in Patients with Cushing's Syndrome and Comorbid Diabetes Mellitus
Strongbridge Biopharma plc (NASDAQ: SBBP) has announced detailed results from the previously reported Phase 3 LOGICS study of Recorlev (levoketoconazole) in patients with endogenous Cushing's syndrome. ...
~ As Previously Reported, LOGICS Met its Primary Endpoint with Statistical Significance ~
While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
DUBLIN, Ireland and TREVOSE, Pa., March 15, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commerc...
Strongbridge Biopharma (SBBP) delivered earnings and revenue surprises of 15.38% and 1.04%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Strongbridge Biopharma (NASDAQ:SBBP) moved higher by 0.6% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 56.00% over the past year ...
~ Submitted New Drug Application (NDA) for RECORLEV® (levoketoconazole) for the Treatment of Endogenous Cushing's Syndrome to U.S. Food & Drug Administration ~
Strongbridge Biopharma plc (NASDAQ: SBBP) has submitted a marketing application seeking approval for Recorlev (levoketoconazole) for the treatment of endogenous Cushing's syndrome, to the FDA. Endogenou...
~ RECORLEV® (levoketoconazole) New Drug Application is Supported by Previously-Reported Positive and Statistically Significant Results from the Phase 3 SONICS and LOGICS Studies ~
DUBLIN, Ireland and TREVOSE, Pa., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commerc...
DUBLIN, Ireland and TREVOSE, Pa., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commerc...
~ Expects to Report KEVEYIS® (dichlorphenamide) Fourth Quarter 2020 Revenue of Approximately $8.2 Million and Full-Year 2020 Revenue of Approximately $30.7 Million, a 41.5 Percent Increase over 2019 Rev...
~ RECORLEV™ (levoketoconazole) Treatment Resulted in Significantly Improved Clinician-Assessed Signs and Symptoms and Patient-Reported Outcomes of Cushing's Syndrome ~ ~ RECORLEV™ (levoketoconazole) Tre...
The shares of small-cap biopharma concern are finally seeing some momentum as they rally off oversold levels. The company posted better-than-expected Q3 results in late October and have some potential c...
DUBLIN, Ireland and TREVOSE, Pa., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commerci...
Strongbridge Biopharma plc (SBBP) CEO John Johnson on Q3 2020 Results - Earnings Call Transcript
Strongbridge Biopharma (SBBP) delivered earnings and revenue surprises of 20.00% and 11.68%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
~ Company on Track to Submit New Drug Application (NDA) for RECORLEV® (levoketoconazole) to the FDA in the First Quarter of 2021 Following the Reporting of Positive Top-line Data from the LOGICS Study i...
DUBLIN, Ireland and TREVOSE, Pa., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commerc...
DUBLIN, Ireland and TREVOSE, Pa., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and comm...
DUBLIN, Ireland and TREVOSE, Pa., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and comm...
NEW YORK, Sept. 14, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Strongbridge Biopharma plc ("Strongbridge" or the "Company") (NYSE: SBBP).
After reporting positive Recorlev Phase 3 top line data, SBBP management demonstrated incredible confidence by guiding investors to expect $250MM-$350MM/year in peak Recorlev sales/year.
~ Company Reported Positive and Statistically Significant Top-Line Results from the Pivotal Phase 3 LOGICS Study of RECORLEV® (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome; To Vi...
~ LOGICS Study Met Primary Endpoint with High Statistical Significance; Results at the End of the Randomized-Withdrawal Phase of the Study Demonstrated that Withdrawing Patients to Placebo Resulted in a...
Recorlev's Cushing's disease phase 3 topline data is due 9/2020. If the data looks good, NDA submission follows. If the data does not look good, SBBP options are very limited.
About SBBP
Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs in the United States. The company offers Keveyis, an oral carbonic anhydrase inhibitor to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. Its clinical-stage product candidates include Recorlev, a cortisol synthesis inhibitor, which is in Phase III clinical trials for the treatment of endogenous Cushing's syndrome; and Veldoreotide, a somato... [Read more...]
| Industry Biotechnology | IPO Date Oct 16, 2015 |
| CEO Matthew Pauls | Employees 72 |
| Stock Exchange NASDAQ | Ticker Symbol SBBP |
Financial Performance
In 2020, SBBP's revenue was $30.73 million, an increase of 41.54% compared to the previous year's $21.71 million. Losses were -$45.08 million, -8.85% less than in 2019.
Analyst Forecasts
According to 6 analysts, the average rating for SBBP stock is "Strong Buy." The 12-month stock price forecast is 5.83, which is an increase of 135.08% from the latest price.